What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Melanoma
Internal medicine, Melanoma, Ipilimumab, Oncology and Pembrolizumab are his primary areas of study.
His biological study spans a wide range of topics, including Surgery and Immunology.
His Melanoma research integrates issues from Cancer and Immunotherapy.
His study in Cancer is interdisciplinary in nature, drawing from both Biopsy and Pathology.
His studies in Ipilimumab integrate themes in fields like Discontinuation and Response Evaluation Criteria in Solid Tumors.
He interconnects Biomarker, V600E and Hazard ratio in the investigation of issues within Oncology.
His most cited work include:
- Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma (758 citations)
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis (538 citations)
- Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy (436 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Melanoma, Internal medicine, Oncology, Ipilimumab and Immunotherapy.
The Melanoma study combines topics in areas such as Cancer, Targeted therapy and Immunology.
Many of his studies on Internal medicine apply to Gastroenterology as well.
His studies deal with areas such as Adjuvant therapy, Metastatic melanoma, Surgery and Cohort as well as Oncology.
His Ipilimumab research is multidisciplinary, incorporating perspectives in Advanced melanoma, Adjuvant, Clinical endpoint, Toxicity and Combination therapy.
His Adverse effect research is multidisciplinary, incorporating elements of Immunosuppression and Discontinuation.
He most often published in these fields:
- Melanoma (100.31%)
- Internal medicine (96.59%)
- Oncology (67.49%)
What were the highlights of his more recent work (between 2020-2021)?
- Internal medicine (96.59%)
- Melanoma (100.31%)
- Oncology (67.49%)
In recent papers he was focusing on the following fields of study:
Alexander M. Menzies mainly focuses on Internal medicine, Melanoma, Oncology, Ipilimumab and Nivolumab.
He usually deals with Internal medicine and limits it to topics linked to Gastroenterology and Adverse effect and Immunosuppression.
His Melanoma research includes themes of Immune checkpoint, Targeted therapy, Interquartile range and Confidence interval.
His research in Oncology focuses on subjects like Metastatic melanoma, which are connected to PALB2, Mutation, Partial response and Somatic cell.
The various areas that he examines in his Ipilimumab study include Pembrolizumab, Metastasis and Systemic therapy.
The study incorporates disciplines such as Neoadjuvant therapy and Clinical trial in addition to Nivolumab.
Between 2020 and 2021, his most popular works were:
- Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). (8 citations)
- Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). (8 citations)
- Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. (4 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His main research concerns Internal medicine, Melanoma, Ipilimumab, Nivolumab and Oncology.
Retrospective cohort study and Cohort study are among the areas of Internal medicine where the researcher is concentrating his efforts.
His work is dedicated to discovering how Retrospective cohort study, Cause of death are connected with Cancer and other disciplines.
He interconnects Positron emission tomography and Histopathology in the investigation of issues within Melanoma.
His work deals with themes such as Pembrolizumab and Systemic therapy, which intersect with Ipilimumab.
His Nivolumab study which covers Targeted therapy that intersects with Clinical trial, Surrogate endpoint and Neoadjuvant therapy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
